Filing search / Intellia Therapeutics, Inc. / "Reimbursement" / Page 2

S-3ASR

EX-4.2

rcnq0wkvhxkiee16bs3

24 Nov 23

Automatic shelf registration

9:30am

S-3ASR

kig2k5

24 Nov 23

Automatic shelf registration

9:30am

S-3ASR

EX-4.1

0h5pn

24 Nov 23

Automatic shelf registration

9:30am

8-K

EX-99.1

zn40fzzzg2iwfxve

9 Nov 23

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

7:45am

8-K

EX-99.1

jel0ugpwkk9yxdcgfy

3 Oct 23

Regeneron and Intellia Announce Expanded Research Collaboration

7:19am

8-K

EX-99.1

ls7j2

3 Aug 23

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

7:45am

8-K

EX-99.1

kier0uyw4xr

4 May 23

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

7:41am

PRE 14A

1k1kx

18 Apr 23

Preliminary proxy

4:16pm

424B5

nmz51uklnmi5akvuqt

1 Dec 22

Prospectus supplement for primary offering

5:09pm

8-K

EX-99.1

iylkpfah

16 Sep 22

Regulation FD Disclosure

7:36am

8-K

EX-99.1

vmebi3k3y6on dqi

24 Jun 22

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of

7:46am